skip to main content

H.R. 2820 (114th): Stem Cell Therapeutic and Research Reauthorization Act of 2015

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

The federal budget process occurs in two stages: appropriations, which set overall spending limits by agency or program, and authorizations, which direct how federal funds should (or should not) be used. Appropriation and authorization provisions are typically made for single fiscal years. A reauthorization bill like this one renews the authorizations of an expiring law.

Christopher “Chris” Smith

Sponsor. Representative for New Jersey's 4th congressional district. Republican.

Read Text »
Last Updated: Oct 6, 2016
Length: 3 pages
Introduced:

Jun 18, 2015
114th Congress, 2015–2017

Status:

Enacted — Signed by the President on Dec 18, 2015

This bill was enacted after being signed by the President on December 18, 2015.

Law:

Pub.L. 114-104

Incorporated Legislation

This bill incorporates provisions from:

S. 2282: Stem Cell Therapeutic and Research Reauthorization Act of 2015

Introduced on Nov 16, 2015. 100% incorporated. (compare text)

History

Jun 18, 2015
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

Jul 23, 2015
 
Considered by Health

A committee held a hearing or business meeting about the bill.

Jul 28, 2015
 
Considered by House Committee on Energy and Commerce

A committee held a hearing or business meeting about the bill.

Jul 29, 2015
 
Ordered Reported

A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.

Sep 8, 2015
 
Passed House (Senate next)

The bill was passed in a vote in the House. It goes to the Senate next. The vote was by voice vote so no record of individual votes was made.

Sep 8, 2015
 
Reported by House Committee on Energy and Commerce

A committee issued a report on the bill, which often provides helpful explanatory background on the issue addressed by the bill and the bill's intentions.

Nov 18, 2015
 
Considered by Senate Committee on Health, Education, Labor, and Pensions

A committee held a hearing or business meeting about the bill.

Dec 3, 2015
 
Text Published

Updated bill text was published as of Reported by Senate Committee.

Dec 9, 2015
 
Passed Senate with Changes (back to House)

The Senate passed the bill with changes not in the House version and sent it back to the House to approve the changes. The vote was by Unanimous Consent so no record of individual votes was made.

Dec 16, 2015
 
House Agreed to Changes

The bill was passed by both chambers in identical form. It goes to the President next who may sign or veto the bill.

Dec 18, 2015
 
Enacted — Signed by the President

The President signed the bill and it became law.

H.R. 2820 (114th) was a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

This bill was introduced in the 114th Congress, which met from Jan 6, 2015 to Jan 3, 2017. Legislation not enacted by the end of a Congress is cleared from the books.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 2820 — 114th Congress: Stem Cell Therapeutic and Research Reauthorization Act of 2015.” www.GovTrack.us. 2015. November 24, 2017 <https://www.govtrack.us/congress/bills/114/hr2820>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.